A Pilot Study in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS)
clinical trial
Press Enter · cited answer in seconds
0 sources
Summary
A Pilot Study in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS) is a clinical trial[1].
Key Facts
- A Pilot Study in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS) is in the country of Italy[2].
- A Pilot Study in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS)'s instance of is recorded as clinical trial[3].
- A Pilot Study in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS)'s start time is recorded as +2018-03-26T00:00:00Z[4].
- A Pilot Study in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS)'s end time is recorded as +2019-01-11T00:00:00Z[5].
- A Pilot Study in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS)'s main subject is recorded as sclerosis[6].
- A Pilot Study in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS)'s main subject is recorded as multiple sclerosis[7].
- A Pilot Study in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS)'s number of participants is recorded as {'unit': '1', 'amount': '+7'}[8].
- A Pilot Study in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS)'s title is recorded as Evaluation of clINical reCovery After a Relapse: a Pilot Study assEssing the Neuronal Effects of D-Aspartate in RR-MS Subjects Treated With IntErferon Beta 1a 44 mcg TIW (INCREASE)[9].
- A Pilot Study in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS)'s short name is recorded as INCREASE[10].
- A Pilot Study in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS)'s minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}[11].
- A Pilot Study in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS)'s ClinicalTrials.gov ID is recorded as NCT03387046[12].
- A Pilot Study in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS)'s maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+55'}[13].
- A Pilot Study in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS)'s research intervention is recorded as methylprednisolone[14].
- A Pilot Study in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS)'s research intervention is recorded as methylprednisolone hemisuccinate[15].
- A Pilot Study in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS)'s research intervention is recorded as prednisolone[16].
- A Pilot Study in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS)'s research intervention is recorded as prednisolone acetate[17].
- A Pilot Study in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS)'s research intervention is recorded as prednisolone 21-phosphate[18].
- A Pilot Study in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS)'s clinical trial phase is recorded as phase II clinical trial[19].
- A Pilot Study in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS)'s research site is recorded as Azienda Ospedaliera di Padova[20].
- A Pilot Study in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS)'s research site is recorded as Regional Hospital San Camillo Forlanini[21].
- A Pilot Study in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS)'s research site is recorded as Agostino Gemelli University Polyclinic[22].
- A Pilot Study in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS)'s study type is recorded as interventional study[23].